Method for detecting hemolysis
AssigneeAlbert Einstein College of Medicine of Yeshiva University
InventorsEdward R. Burns, Vadiraja Murthy
Life of this patent
Estimating the term…
Abstract
This invention provides a method for determining the presence of hemolyzed erythrocytes in blood by detecting erythrocyte adenylate kinase in a serum sample from the blood. This invention also provides a method for diagnosing a hemolytic condition in a subject suspected to be suffering from hemolysis, as well as a method for monitoring hemolysis in a subject undergoing treatment for a hemolytic condition.
Claims9
A method for diagnosing erythrocyte hemolysis in a subject who is suspected of having erythrocyte hemolysis in vivo, the method consiting essentially of the steps of:
- (a) obtaining a serum sample from a subject who is suspected of having erythrocyte hemolysis in vivo;
- and
- (b) determining the level of erythrocyte adenylate kinase activity in said sample, the presence of at least about 20 U/L erythrocyte adenylate kinase activity in said sample being indicative of erythrocyte hemolysis in vivo in said subject.
A method for diagnosing erythrocyte hemolysis in a subject who may have erythrocyte hemolysis, the method comprising the steps of:
- (a) obtaining a serum sample from the subject;
- and
- (b) determining the level of erythrocyte adenylate kinase activity in the sample by
- determining a value for total adenylate kinase activity in the serum sample;
- determining a value for percentage erythrocyte adenylate kinase in the sample;
- and
- determining erythrocyte adenylate kinase activity in the sample by multiplying the value for percentage erythrocyte adenylate kinase by the value for total adenylate kinase activity,
- the presence of at least about 20 U/L erythrocyte adenylate kinase activity in the sample being indicative of erythrocyte hemolysis in the subject.
A method for diagnosing erythrocyte hemolysis in a subject who may have erythrocyte hemolysis, the method comprising the steps of:
- (a) obtaining a serum sample from the subject;
- and
- (b) determining the level of erythrocyte adenylate kinase activity in the sample using an antibody that is specific for and binds to erythrocyte adenylate kinase,
- the presence of at least about 20 U/L erythrocyte adenylate kinase activity in the sample being indicative of erythrocyte hemolysis in the subject.
Dependencies are inferred from the claim text.